Уважаемые коллеги, доброго времени суток! Представляем вам американское научное издание Biology of Reproduction. Журнал имеет первый квартиль, издаётся в Society for the Study of Reproduction, его SJR за 2022 г. равен 0,991, пятилетний импакт-фактор 4,522, печатный ISSN - 0006-3363, электронный - 1529-7268, предметные области - Репродуктивная медицина, Медицина (общие вопросы), Клеточная биология (цитология). Вот так выглядит обложка:
Здесь два редактора - Романа Новак, контактные данные - ranowak@illinois.edu
и Мари Зелински - zelinski@ohsu.edu.
Дополнительные публикационные контакты - wyan@med.unr.edu, biolre.editorialoffice@jjeditorial.com.
Адрес издания - https://academic.oup.com/biolreprod?login=false
Пример статьи, название - Mitochondrial uncouplers impair human sperm motility without altering ATP content. Заголовок (Abstract) - In human spermatozoa, the electrochemical potentials across the mitochondrial and plasma membranes are related to sperm functionality and fertility, but the exact role of each potential has yet to be clarified. Impairing sperm mitochondrial function has been considered as an approach to creating male or unisex contraceptives, but it has yet to be shown whether this approach would ultimately block the ability of sperm to reach or fertilize an egg. To investigate whether the mitochondrial and plasma membrane potentials are necessary for sperm fertility, human sperm were treated with two small-molecule mitochondrial uncouplers (Niclosamide Ethanolamine and BAM15) that depolarize membranes by inducing passive proton flow, and evaluated the effects on a variety of sperm physiological processes. BAM15 specifically uncoupled human sperm mitochondria while Niclosamide Ethanolamine induced proton current in the plasma membrane in addition to depolarizing the mitochondria. Additionally, both compounds significantly decreased sperm progressive motility with Niclosamide Ethanolamine having a more robust effect. However, these uncouplers did not reduce sperm ATP content or impair other physiological processes, suggesting that human sperm can rely on glycolysis for ATP production if mitochondria are impaired. Thus, systemically delivered contraceptives that target sperm mitochondria to reduce their ATP production would likely need to be paired with sperm-specific glycolysis inhibitors. However, since Niclosamide Ethanolamine impairs sperm motility through an ATP-independent mechanism, and Niclosamide is FDA-approved and not absorbed through mucosal membranes, it could be a useful ingredient in on-demand, vaginally-applied contraceptives.